TargetBeta
SV2A
synaptic vesicle glycoprotein 2A · also SV2, KIAA0736, SLC22B1 · Solute carrier family 22
2 programs in company-led studies act on SV2A, from 1 company: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Levetiracetamrule | UCB | phase 4 | 730 running | CACNA1B | ChEMBL |
| brivaracetamrule | UCB | phase 3 | 423 running | – | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Epilepsies, Partial, 2 programs
- Epilepsy, 2 programs
- Seizures, 2 programs
- Cognitive Dysfunction, 1 program
- Epilepsy, Absence, 1 program
- Epilepsy, Generalized, 1 program
- Myoclonus, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 16, 2029brivaracetam · UCB · phase 3 · NCT06315322
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.